AI assistant
ARIX BIOSCIENCE PLC Board/Management Information 2019
4968_rns_2019-10-02_1e5a710e-85bb-4d5d-8167-0f5a532b391f.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
Arix Bioscience Plc - Management change
PR Newswire
London, October 1
Arix Bioscience plc
Management change
LONDON, 2 October 2019: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the departure of Chief Financial Officer, James Rawlingson and promotion of Group Financial Controller, Marcus Karia to Group Finance Director. These changes take place with immediate effect.
Joe Anderson, Chief Executive Officer commented:
“On behalf of the board I’d like to thank James for his contribution to Arix in the first stage of our development and wish him well in his future endeavours.”
Enquiries:
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0)203 950 9144
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
